← Back to Search

Akynzeo for Chemotherapy-Induced Nausea and Vomiting

Phase 2

Recruiting

Research Sponsored by Simon Williamson Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 days post chemotherapy

Awards & highlights

Study Summary

This trial aims to find better ways to prevent nausea and vomiting in cancer patients from chemotherapy.

Who is the study for?

This trial is for patients who have never had chemotherapy before and are about to receive treatment for lung or breast cancer that often causes nausea and vomiting. It's not open to those who've already undergone chemotherapy.Check my eligibility

What is being tested?

The study tests Akynzeo, a medication intended to prevent nausea and vomiting in patients undergoing certain types of intense chemotherapy, based on guidelines and literature data.See study design

What are the potential side effects?

Akynzeo may cause side effects such as headache, constipation, tiredness, dizziness, upset stomach, changes in liver function tests, and allergic reactions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 days post chemotherapy

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 days post chemotherapy

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 days post chemotherapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

COMPELETE RESPONSE, no vomiting or use of rescue medications

Trial Design

2Treatment groups

Active Control

Group I: oLANZAPINE and Akynzeo to patients receiving highly emetogenicActive Control1 Intervention

olANZAPINE plus Akynzeo

Group II: AKYNZEO for patient receiving MECActive Control1 Intervention

Add Akynzeo to 5HT3 And dexamethasone

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Simon Williamson ClinicLead Sponsor

Helsinn Healthcare SAIndustry Sponsor

41 Previous Clinical Trials

9,475 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA sanctioned AKYNZEO for people undergoing MEC?

"Our team assigned AKYNZEO a score of 2 on the safety scale since it is in Phase 2 trials, and as such there are some data points that suggest its efficacy but no evidence to support it."

Answered by AI

Is this medical experiment currently enlisting participants?

"According to the latest information available on clinicaltrials.gov, this investigative research is still seeking participants. The study was first introduced on September 9th 2023 and has since been amended as of October 1st 2023."

Answered by AI

How many participants have been admitted to this experiment?

"Affirmative. The details on clinicaltrials.gov verify that this trial, which was initially published on September 9th 2023, is currently recruiting patients. One hundred people are needed from one medical centre for participation in the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

2023. "Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06065722.